The FDA has accepted Medicines Company's (MDCO +1.7%) filing of a new drug application (NDA) for the firm's Oritavancin intravenous antibiotic, with priority review, for the treatment of certain types of skin infections. (PR)
Q4 adjusted net income decreased 38% to $17.7M.
Total net income dropped to $1.2M from $20.7M.
Amortization of acquired intangible assets 10.1M.
During Q4, Medicines Company completed the acquisition of Rempex Pharmaceuticals and a co-promotion partnership with Boston Scientific. (PR)